#USA #Burlingame #Enliven Therapeutics #ELVN-001 #CML Treatment

Enliven Therapeutics Releases Updated Phase 1 Clinical Data and FDA Collaboration

On June 11, 2026, Enliven Therapeutics, a biopharmaceutical company dedicated to developing small molecule therapies, provided significant updates regarding their clinical trial data for ELVN-001, a drug aiming to treat chronic myeloid leukemia (CML). This presentation took place during the European Hematology Association Congress held in Stockholm, Sweden, highlighting a strong alignment with the FDA on key components relevant to upcoming Phase 3 trials.

Promising Clinical Results

In their Phase 1 ENABLE trial, Enliven reported an overall major molecular response (MMR) rate of 61% and an MMR accomplishment of 48% at the 24-week mark specifically within the 80 mg daily cohort. Furthermore, across all Phase 1b patients, results indicated a favorable 67% overall MMR with an impressive 55% MMR achievement by the same 24-week period. These findings suggest that ELVN-001 demonstrates substantial efficacy, particularly among patients who have previously undergone treatment with multiple tyrosine kinase inhibitors (TKIs).

The data reveals the safety profile of ELVN-001 as generally favorable, with 161 participants enrolled and a median treatment duration stretching 35 weeks. Dr. Dennis Kim from the Princess Margaret Cancer Centre expressed optimism over the data, noting the critical need for effective treatments that manage safety and durability in patients with CML who have not responded sufficiently to existing therapies.

FDA Collaboration

The interaction with the FDA has solidified the recommended Phase 3 dose at 80 mg once daily and clarified the inclusion criteria for patients who have been treated with at least one prior TKI. This collaboration marks an essential step as Enliven prepares to launch its pivotal ENABLE-2 trial later this year. Helen Collins, Enliven’s Chief Medical Officer, emphasized the importance of maintaining high response rates across various treatment lines, bolstering the drug's profile relative to competing therapies.

Background on ELVN-001

ELVN-001 represents a novel and highly selective small molecule kinase inhibitor designed to specifically address the BCR-ABL fusion that drives cancer in CML patients. The ENABLE study is structured to both assess safety and tolerability while determining the ideal dosing for continued evaluations aimed at patients with CML, whether they present T315I mutations or not. This drug was developed to combat resistance phenomena often observed in prevalent treatments, demonstrating relevance to the clinical landscape where unmet needs persist.

Recent data showcased comparable response rates regardless of prior exposure to asciminib, an existing treatment. By 24 weeks, 30% of patients on the 80 mg QD cohort achieved a deep molecular response (DMR), affirming the drug's potential in a heavily pretreated patient population where alternatives have repeatedly fallen short.

Conclusion

As Enliven Therapeutics gears up for the next phases of clinical trials, the improvements showcased through the ENABLE trial results could position ELVN-001 as a pivotal therapeutic option for patients battling chronic myeloid leukemia. With a strategic focus on safety, tolerability, and in-depth efficacy, the path ahead looks promising for this innovative treatment.

To learn more, interested parties can access more information via Enliven's official website or the investor relations section related to the ongoing developments of ELVN-001.